Regulatory FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial Pharmaceutical TechnologyREGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.Rare DiseaseRead full story pharminent August 25, 2026 (Last updated: August 25, 2026) Pharmaceutical Technology REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II. Rare Disease Read full story Post navigation Previous: Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 BillionNext: FDA greenlights Roche’s biomarker blood test for Alzheimer’s Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026